study_id,year,design,effect_type,effect_point,ci_low,ci_high,n_treat,n_ctrl,risk_of_bias,doi,journal_id,intervention,control,outcome,duration_weeks,population
creatine_2018_1,2018,RCT,MD,-2.335,-2.812,-1.859,40,112,low,10.9008/j.eur_heart_j.2018.8308,eur_heart_j,Creatine supplement,Placebo,Serum creatinine (mg/dL),12,Elderly adults
creatine_2014_2,2014,cohort,MD,-1.216,-1.746,-0.687,113,36,low,10.1813/j.kidney_int.2014.3669,kidney_int,Creatine supplement,Control group,Serum creatinine (mg/dL),6,Patients with CKD
creatine_2018_3,2018,RCT,MD,-2.092,-2.55,-1.634,112,26,some,10.3837/j.neuropsychopharmacol.2018.1138,neuropsychopharmacol,Creatine supplement,Placebo,Serum creatinine (mg/dL),8,Elderly adults
creatine_2023_4,2023,RCT,MD,0.031,-0.458,0.521,57,52,some,10.7506/j.predatory_journal_1.2023.2676,predatory_journal_1,Creatine supplement,Placebo,eGFR (mL/min/1.73mÂ²),16,Elderly adults
